具有不同疾病阶段和抗病毒治疗的慢性乙型肝炎病毒感染患

StephenW

Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15732. [Epub ahead of print]
Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J1,2, Huang R2, Chen Y3, Liu Y3, Wang J2, Yan X2, Zhang Z2, Wu C1,2.
Author information

1
    Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
2
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
3
    Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.

Abstract
BACKGROUND:

Soluble programmed death-1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) play a role in immune regulation of chronic hepatitis B virus (HBV) infection.
AIM:

To investigate the profiles of serum sPD-1 and sPD-L1 in chronic HBV-infected patients with different disease phases and after anti-viral treatment.
METHODS:

A total of 99 chronic HBV-infected patients were enrolled and divided into HBeAg-positive chronic HBV infection (EPI) group, HBeAg-positive chronic hepatitis B (EPH) group, HBeAg-negative chronic hepatitis B (ENH) group and HBeAg-negative chronic HBV infection (ENI) group. Eleven healthy subjects were included as healthy controls (HCs). Thirty-two EPH patients received anti-viral treatment with nucleos(t)ide analogues and were followed up to 5 years. Serum sPD-1 and sPD-L1 levels were detected by Multiplex Immunoassays.
RESULTS:

Serum sPD-1 and sPD-L1 levels of chronic HBV infected patients were significantly higher than that of HCs (P < 0.01). Patients in EPH, ENH and EPI groups had higher serum sPD-1 and sPD-L1 levels than that in HCs (P < 0.01). After anti-viral treatment, serum sPD-1 and sPD-L1 levels declined rapidly. EPH patients with HBeAg clearance after 2 years of anti-viral treatment showed lower baseline HBeAg and sPD-1 levels compared to those without HBeAg clearance.
CONCLUSIONS:

Serum sPD-1 and sPD-L1 levels varied among chronic HBV infected patients with different disease phases. Lower baseline sPD-1 levels were associated with HBeAg clearance after 2 years of anti-viral treatment in EPH patients.

© 2020 John Wiley & Sons Ltd.

PMID:
    32363582
DOI:
    10.1111/apt.15732

StephenW

食品药理学。 2020年5月3日。doi：10.1111 / apt.15732。 [Epub提前发布]
具有不同疾病阶段和抗病毒治疗的慢性乙型肝炎病毒感染患者的血清可溶性程序性死亡1和程序性死亡配体1水平概况。
夏J1,2，黄R2，陈Y3，刘Y3，王J2，严X2，张Z2，吴C1,2。
作者信息

1个
    南京医科大学南京鼓楼医院临床学院传染病科，江苏南京
2
    南京大学医学院附属医院南京鼓楼医院感染科，江苏南京
3
    南京大学医学院附属医院南京鼓楼医院检验科，江苏南京

抽象
背景：

可溶性程序性死亡1（sPD-1）和可溶性程序性死亡配体1（sPD-L1）在慢性乙型肝炎病毒（HBV）感染的免疫调节中发挥作用。
目标：

调查慢性乙肝病毒感染的不同疾病阶段和抗病毒治疗后患者血清sPD-1和sPD-L1的概况。
方法：

共有99例慢性HBV感染患者入选，分为HBeAg阳性慢性HBV感染（EPI）组，HBeAg阳性慢性乙肝（EPH）组，HBeAg阴性慢性乙肝（ENH）组和HBeAg阴性慢性HBV感染（ENI）组。纳入了11名健康受试者作为健康对照（HCs）。 32例EPH患者接受了核苷酸（t）ide类似物的抗病毒治疗，并随访了5年。通过多重免疫测定法检测血清sPD-1和sPD-L1水平。
结果：

慢性HBV感染患者的血清sPD-1和sPD-L1水平显着高于HCs（P <0.01）。 EPH，ENH和EPI组的患者血清sPD-1和sPD-L1水平高于HCs（P <0.01）。抗病毒治疗后，血清sPD-1和sPD-L1水平迅速下降。经过2年抗病毒治疗后具有HBeAg清除率的EPH患者的基线HBeAg和sPD-1水平低于无HBeAg清除率的患者。
结论：

不同疾病阶段的慢性HBV感染患者的血清sPD-1和sPD-L1水平有所不同。 EPH患者经过2年抗病毒治疗后，较低的基线sPD-1水平与HBeAg清除率相关。

分级为4 +©2020 John Wiley＆Sons Ltd.

PMID：
    32363582
DOI：
    10.1111 / apt.15732

StephenW

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.15732